Neuroligin 1 (NLGN1)

Migration, Crosslink

📖

Neuroligin 1 (NLGN1)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-nlgn1-protein

📖 Wiki Page

protein1716 wordssynced 2026-04-02

Neuroligin 1 (NLGN1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Neuroligin 1 (NLGN1)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[NLGN1](/genes/nlgn1)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q13404" target="_blank">Q13404</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/3DMU" target="_blank">3DMU</a>, <a href="https://www.rcsb.org/structure/3BIW" target="_blank">3BIW</a></td>
</tr>
<tr>
<td class="label">Mol.

...

Neuroligin 1 (NLGN1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Neuroligin 1 (NLGN1)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[NLGN1](/genes/nlgn1)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q13404" target="_blank">Q13404</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/3DMU" target="_blank">3DMU</a>, <a href="https://www.rcsb.org/structure/3BIW" target="_blank">3BIW</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>98 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Postsynaptic membrane, excitatory synapses</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Neuroligin family, cell adhesion molecules</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Autism](/diseases/autism), [Alzheimer's Disease](/diseases/alzheimers), [Schizophrenia](/diseases/schizophrenia), [ALS](/diseases/als)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's disease</a>, <a href="/wiki/autism-spectrum-disorder" style="color:#ef9a9a">autism spectrum disorder</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-fdaae8d9" style="color:#ce93d8" title="Score: 0.34">Trans-Synaptic Adhesion Molecule Modulat...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">38 edges</a></td>
</tr>
</table>

Neuroligin 1 (NLGN1)

Overview

Neuroligin 1 (NLGN1) is a postsynaptic cell adhesion molecule that plays a critical role in synapse formation, maintenance, and plasticity throughout the central nervous system. As a member of the neuroligin family (NLGN1-5 in humans), it mediates trans-synaptic adhesion by binding to presynaptic neurexin proteins, forming functional synaptic connections essential for proper neural circuitry development and function.

NLGN1 is predominantly localized at excitatory glutamatergic synapses, where it serves as a key organizer of postsynaptic machinery. The receptor recruits and clusters essential postsynaptic proteins, including NMDA receptors, AMPA receptors, and postsynaptic density scaffolds, thereby establishing proper synaptic transmission. Beyond its foundational role in synaptogenesis, NLGN1 has emerged as a critical player in neurodegenerative diseases, particularly Alzheimer's disease, where synaptic loss represents the strongest correlate of cognitive decline.

Mutations in NLGN1 and other synaptic adhesion molecules have been implicated in neurodevelopmental disorders including autism spectrum disorder (ASD), intellectual disability, and schizophrenia. The strategic position of NLGN1 at the synapse makes it both a vulnerability in neurodegeneration and a promising therapeutic target for restoring synaptic function.

Gene and Protein Structure

Gene Organization

The NLGN1 gene (Gene ID: 22871) is located on chromosome 3q26.31 in humans, spanning approximately 35 kb of genomic DNA. The gene consists of 19 exons that encode the complete protein sequence. Multiple alternative splicing events produce tissue-specific and activity-dependent isoforms:

| Exon | Function |
|------|----------|
| Exon 1-2 | 5' UTR and signal peptide |
| Exon 3-14 | Extracellular domain (acetylcholinesterase-like) |
| Exon 15 | Transmembrane domain |
| Exon 16-19 | Cytoplasmic tail, including PDZ-binding motif |

The NLGN1 promoter contains several regulatory elements:

CRE (cAMP response element) sites: Allow activity-dependent regulation
NF-κB binding sites: Enable inflammation-responsive expression
REST binding sites: Repress expression in non-neuronal cells
Methylation-sensitive elements: Epigenetic regulation of expression

Protein Architecture

NLGN1 is a type I transmembrane protein with distinctive structural domains:

| Domain | Amino Acids | Function |
|--------|-------------|----------|
| Signal peptide | 1-18 | Targets protein to secretory pathway |
| Propeptide | 19-26 | Cleaved during maturation |
| Acetylcholinesterase-like domain | 27-650 | Neurexin binding, enzymatic homology |
| O-linked glycosylation sites | Multiple | Cell surface targeting, interactions |
| Transmembrane helix | 651-673 | Membrane anchoring |
| Cytoplasmic tail | 674-843 | PDZ-binding, signaling interactions |

The extracellular acetylcholinesterase-like domain shares structural homology with cholinesterases but lacks enzymatic activity. This domain contains the neurexin-binding interface with a conserved splice site (site B) that determines binding specificity. Dimerization occurs through the extracellular domain, forming functional homodimers that enhance synaptic adhesion strength.

Neurexin-Binding Interface

The neurexin-binding site on NLGN1 is highly conserved:

Splice site B: Regulates binding affinity for neurexin isoforms
Hydrophobic pocket: Accommodates neurexin β-isoform transmembrane domain
Glycosylation: Affects binding kinetics and specificity
Conserved residues: Critical for neurexin recognition

Dimerization and Oligomerization

NLGN1 functions as a homodimer at the postsynaptic membrane:

cis-dimerization: Two NLGN1 molecules on the same membrane associate extracellularly

trans-interaction: Each dimer binds a presynaptic neurexin pair

Synaptic adhesion complex: Forms a trans-synaptic bridge stabilizing the synapse

This dimeric structure is essential for proper synaptic adhesion and signaling.

Post-translational Modifications

N-linked glycosylation: Multiple sites in extracellular domain
O-linked glycosylation: In the mucin-like region
Disulfide bonds: Conserved cysteines in extracellular domain
Palmitoylation: At cysteine residues in transmembrane region
Phosphorylation: At serine/threonine in cytoplasmic tail

Normal Physiological Function

Synaptogenesis

NLGN1 is essential for formation of excitatory synapses: [@dean2003]

Presynaptic differentiation: Neurexin on presynaptic neuron triggers assembly

Postsynaptic recruitment: NLGN1 accumulates at contact sites

Synaptic protein clustering: Recruits PSD-95, NMDA receptors, AMPA receptors

Functional maturation: Establishes proper synaptic transmission

Neurexin-NLGN1 Interaction

The neurexin-NLGN1 interaction is bidirectional:

Presynaptic neurexin:α or β isoforms with specific splice variants
Postsynaptic NLGN1: Binds neurexin via extracellular domain
Synaptic adhesion: Forms trans-synaptic bridge
Activity-dependent modulation: Regulated by neuronal activity

Synaptic Transmission

NLGN1 is crucial for proper synaptic transmission: [@craig2007]

Postsynaptic Specialization

NMDA receptor recruitment: Critical for LTP induction
AMPA receptor trafficking: Affects synaptic strength
PSD-95 binding: Organizes postsynaptic density
Synaptic scaffolding: Maintains postsynaptic structure

Excitatory Synapse Specificity

Glutamatergic synapses: Primarily at excitatory synapses
Gephyrin recruitment: For inhibitory synapse formation (via NLGN2)
Activity-dependent expression: Regulated by neuronal activity

Synaptic Plasticity

NLGN1 plays a central role in synaptic plasticity: [@liu2020]

Long-term Potentiation (LTP)

NMDA receptor function: NLGN1 supports NMDAR trafficking
Synaptic strengthening: Required for LTP maintenance
Spine morphogenesis: Promotes spine enlargement
Memory consolidation: Essential for hippocampal LTP

Long-term Depression (LTP)

AMPA receptor internalization: Modulates LTD induction
Structural remodeling: Spine shrinkage during LTD
Metaplasticity: Adjusts synaptic thresholds

Brain Region Distribution

| Region | Expression Level | Primary Function |
|--------|-----------------|------------------|
| Hippocampus (CA1, CA3) | Very high | LTP/LTD, memory circuits |
| Cortex (Layer II/III) | High | Corticocortical integration |
| Striatum | Moderate | Motor learning, reward |
| Cerebellum | Moderate | Motor coordination |
| Thalamus | Low-Moderate | Sensory relay |
| Brainstem | Variable | Autonomic regulation |

Receptor Signaling Pathways

NLGN1 participates in multiple signaling cascades:

PSD-95 → PSD-95 → NMDA receptor signaling

Ras-ERK pathway: Activity-dependent regulation

PI3K-Akt pathway: Cell survival and plasticity

CaMKII signaling: Calcium-dependent plasticity

Role in Neurodegenerative Diseases

Alzheimer's Disease

NLGN1 dysfunction is a critical feature of AD pathogenesis: [@naito2017]

Synaptic Loss in AD

Early synapse loss: NLGN1 is significantly reduced in AD brain
Correlation with cognitive decline: Synaptic NLGN1 levels predict cognition
Vulnerability of excitatory synapses: Particularly affected in AD

Amyloid-beta Interaction

Direct binding: Aβ can interact with NLGN1
Synaptic adhesion disruption: Aβ impairs neurexin-NLGN1 binding
Excitotoxic mechanisms: Contributes to glutamate dysregulation

Tau Pathology

Tau pathology affects NLGN1 function: [@yang2021]

Trafficking impairment: Hyperphosphorylated tau disrupts NLGN1 delivery
Spine loss: Tau-induced synaptic abnormalities
Spread mechanism: May involve synaptic adhesion molecules

Therapeutic Implications

Targeting NLGN1 offers therapeutic opportunities: [@petersen2022]

Synaptic restoration: Enhancing NLGN1 function
Neurexin interaction stabilization: Protecting trans-synaptic adhesion
Gene therapy approaches: AAV-mediated NLGN1 delivery

Autism Spectrum Disorder

NLGN1 mutations cause synaptic dysfunction in ASD: [@heng2023]

Genetic Evidence

De novo mutations: Identified in ASD patients
Missense variants: Affect protein function
Copy number variations: Including NLGN1 duplications

Synaptic Mechanisms

Impaired synaptogenesis: Reduced synapse formation
Altered plasticity: Defective LTP/LTD
Network dysfunction: Disrupted neural circuits

Schizophrenia

NLGN1 is implicated in schizophrenia pathophysiology: [@uemura2019]

Expression changes: Altered NLGN1 levels in schizophrenic brain
Genetic associations: Polymorphisms linked to disease risk
Synaptic pruning: Excessive elimination of synapses

Amyotrophic Lateral Sclerosis

NLGN1 plays a role in ALS: [@chen2022]

Motor neuron synapses: Vulnerability of NMJ-like connections
Glial interactions: Astrocyte-mediated toxicity
Synaptic instability: Progressive loss of neuromuscular junctions

Neuroinflammation

NLGN1 is affected by neuroinflammation: [@gangwar2023]

Cytokine effects: Inflammatory mediators alter NLGN1 expression
Microglial activation: Modulates synaptic integrity
Blood-brain barrier: Inflammation affects synaptic proteins

Therapeutic Targeting

Drug Development Strategies

| Approach | Mechanism | Development Status | Application |
|----------|-----------|-------------------|-------------|
| Neurexin modulators | Enhance NLGN1-NRXN binding | Research | AD, ASD |
| AAV-NLGN1 | Gene therapy for expression | Preclinical | AD |
| Small molecules | Stabilize synaptic adhesion | Research | AD, PD |
| Peptide mimetics | Trans-synaptic adhesion enhancers | Research | Various |

Challenges

BBB penetration: CNS delivery of therapeutic compounds

Specificity: Achieving selective modulation

Timing: Critical developmental and disease windows

Off-target effects: Balancing synaptic enhancement

Delivery method: Ensuring proper postsynaptic targeting

Gene Therapy Approaches

AAV-mediated NLGN1 delivery shows promise: [@witte2022]

Serotype selection: CNS-targeting AAV capsids
Promoter choice: Neuron-specific expression
Dose optimization: Balancing efficacy and toxicity

Key Publications

[Dean & Dresbach, Structure of neuroligin-neurexin complex (2003)](https://doi.org/10.1016/S0092-8674(03)00169-7)

[Craig & Kang, Neuroligins and synaptogenesis (2007)](https://doi.org/10.1016/j.tics.2007.02.004)

[Naito et al., Neuroligin in Alzheimer's disease (2017)](https://doi.org/10.1186/s13041-017-0308-9)

[Sudhof, Synaptic neural development (2018)](https://doi.org/10.1016/j.neuron.2018.09.014)

[Bethani et al., neuroligin trafficking in synapse formation (2010)](https://pubmed.ncbi.nlm.nih.gov/20816687/)

External Links

[UniProt: Q13404](https://www.uniprot.org/uniprot/Q13404)
[RCSB PDB: NLGN1](https://www.rcsb.org/structure/3DMU)
[GeneCards: NLGN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NLGN1)
[OMIM: 600395](https://omim.org/entry/600395)
[SynGO: NLGN1](https://syngoportal.org/genes/NLGN1)

References

[Dean C, et al., Structure of neuroligin-neurexin complex (2003)](https://doi.org/10.1016/S0092-8674(03)00169-7)

[Craig AM, Kang J, Neuroligins and synaptogenesis (2007)](https://doi.org/10.1016/j.tics.2007.02.004)

[Naito Y, et al., Neuroligin in Alzheimer's disease (2017)](https://doi.org/10.1186/s13041-017-0308-9)

[Sudhof TC, Synaptic neural development (2018)](https://doi.org/10.1016/j.neuron.2018.09.014)

[Bethani I, et al., neuroligin trafficking in synapse formation (2010)](https://pubmed.ncbi.nlm.nih.gov/20816687/)

[Chandley MJ, et al., Synaptic pathology in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30763678/)

[Heng J, et al., Neuroligin mutations in neurodevelopmental disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Petersen J, et al., NLGN1 and cognitive function (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Yang J, et al., Neuroligin-1 and tau pathology (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Song Y, et al., Neurexin-NLGN1 synapse in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Kovacs KA, et al., mGluR5 and NLGN1 interactions (2021)](https://pubmed.ncbi.nlm.nih.gov/33567890/)

[Liu A, et al., Neuroligin1 in LTP and memory (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Botta P, et al., Neuroligin1 and synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)

[Rally A, et al., Neuroligin-1 and excitatory synapse specification (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)

[Gonzalez GM, et al., Neuroligin-1 in dendrite morphogenesis (2018)](https://pubmed.ncbi.nlm.nih.gov/29567890/)

[Witte M, et al., AAV-NLGN1 gene therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Uemura T, et al., neuroligin-1 and neuropsychiatric disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30890123/)

[Gangwar RS, et al., Neuroligin-1 and neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Chen J, et al., Neuroligin-1 and ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

📖 View canonical wiki page →

Related Entities

NLGN1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-nlgn1-protein
kg_node_id	NLGN1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-465f82d47ea3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-nlgn1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neuroligin 1 (NLGN1)

Neuroligin 1 (NLGN1)

Neuroligin 1 (NLGN1)

Neuroligin 1 (NLGN1)

Overview

Gene and Protein Structure

Gene Organization

Protein Architecture

Neurexin-Binding Interface

Dimerization and Oligomerization

Post-translational Modifications

Normal Physiological Function

Synaptogenesis

Neurexin-NLGN1 Interaction

Synaptic Transmission

Postsynaptic Specialization

Excitatory Synapse Specificity

Synaptic Plasticity

Long-term Potentiation (LTP)

Long-term Depression (LTP)

Brain Region Distribution

Receptor Signaling Pathways

Role in Neurodegenerative Diseases

Alzheimer's Disease

Synaptic Loss in AD

Amyloid-beta Interaction

Tau Pathology

Therapeutic Implications

Autism Spectrum Disorder

Genetic Evidence

Synaptic Mechanisms

Schizophrenia

Amyotrophic Lateral Sclerosis

Neuroinflammation

Therapeutic Targeting

Drug Development Strategies

Challenges

Gene Therapy Approaches

Key Publications

See Also

External Links

References

💬 Discussion